FTC Sues to Block Cencora's $3.5B MWI-Covetrus Deal: Leverage Impact & Sector Repricing Analysis

Event Summary

As reported by Bloomberg Law and Reuters, the U.S. Federal Trade Commission filed a lawsuit in the Southern District of New York seeking to block Covetrus's proposed $3.5 billion acquisition of MWI Animal Health, the veterinary distribution unit of Cencora Inc. (NYSE: COR). The FTC was joined by a multistate coalition of 21 state attorneys general, including California's AG. The legal basis is Section 7 of the Clayton Act, with regulators arguing the deal would substantially lessen competition in U.S. veterinary product distribution.

According to SEC filings, the deal — announced February 17, 2026 — would have delivered Cencora $1.25 billion in upfront cash, $800 million in perpetual payment-in-kind preferred units, and $1.45 billion in common units of CVET TopCo. Covetrus is privately held and backed by Clayton, Dubilier & Rice and TPG. The FTC contends Covetrus and MWI are the two largest U.S. veterinary-product distributors, competing directly on pricing, rebates, and service-contract negotiations across pharmaceuticals, vaccines, and medical equipment.

Leverage Impact Analysis

COR is trading at $356.00 (24h range: $350.71–$356.55, +1.98%), suggesting the market has not yet fully priced in litigation risk — or is treating today's move as noise ahead of a potential reassessment.

For leveraged COR CFD positions, this event is a classic deal-certainty shock. Consider a trader holding a 50x long COR CFD entered at $356.00: a 5% drawdown to ~$338 would require only a $0.356/share adverse move per unit of margin — meaning a sustained negative re-rating on deal-break probability could wipe a 5% margin buffer rapidly. Traders should monitor for any gap-down sessions if court proceedings accelerate or Cencora issues a formal disclosure on deal timing.

Short-side setups carry their own risk: if Cencora announces a consent decree, divestiture remedy, or litigation settlement that partially salvages the $1.25B cash tranche, a sharp squeeze on existing short positions is plausible. Check crypto funding rates mechanics as an analogy — antitrust outcomes can produce similarly asymmetric squeezes in single-stock CFDs.

Position sizing discipline is critical here. This is a binary regulatory event with an uncertain timeline; standard volatility-based sizing underestimates tail risk around court milestones.

Cross-Market Impact

The direct cross-market read-through hits pharmaceutical distribution peers. McKesson Corporation and Cardinal Health, Inc. face a secondary signal: aggressive FTC enforcement in distribution consolidation raises the regulatory risk premium for any pending or contemplated deals across healthcare supply chains. Zoetis Inc., as the dominant veterinary pharmaceutical manufacturer, faces a nuanced read — a blocked deal preserves distributor competition, potentially maintaining pricing pressure on manufacturers rather than allowing a consolidated buyer to extract deeper rebates.

Beyond healthcare, this reinforces the cross-sector acquisition repricing theme: private-equity-backed healthcare roll-ups face elevated scrutiny, extending deal timelines and discount rates for comparable transactions. No meaningful crypto, forex, or commodity transmission is identifiable — this is a single-sector antitrust event.

Trading Considerations

Key levels for COR: immediate support at the 24h low of $350.71; a close below that opens a re-test of pre-deal-announcement levels, which traders should identify via volume profile. Resistance sits at $356.55 (24h high). The stock's +1.98% session gain suggests the lawsuit's negative implications may not yet be consensus — watch for institutional repositioning once sell-side updates hit.

Catalysts to monitor: federal court preliminary injunction hearings, any Cencora 8-K filings updating deal status or accounting treatment, and state AG developments. As covered in our acquisition arbitrage guide, deal-break scenarios in antitrust litigation tend to reprice the target stock toward pre-announcement levels over weeks, not days.

Trade Cencora, Inc. on CoinUnited.io

Trade COR with up to 1000x leverage → | Create Free Account

_Availability and maximum leverage depend on product, jurisdiction and account eligibility. Leverage amplifies losses and positions can be liquidated._